Avid Bioservices Inc (CDMO)

[entdoc]

and thales, about SK wanting to have FDA product approved within 2-5 years.... "and taking into account slippage and we are talking 7.." Time to production will shorten in the future, and in some cases, dramatically. The public will not be fooled long, and the demand is obvious for safe cancercidal agents with unique MOAs, witness Cotara and Bavi-both with definite therapeutic utility--proven utility IMO. We are witnessing a bewildering denouement of huge proportions. Interesting to see who gets the most money out of it.